Multiple myeloma: Patients with high-risk cytogenetics need high-dose therapy
A meta-analysis suggests a survival benefit for these patients compared with patients who are at standard risk
Patients with newly diagnosed multiple myeloma and high-risk cytogenetics should be offered upfront rather than delayed high-dose therapy consolidation, a new analysis suggests.
According to US researchers, early autologous stem cell transplantation leads to favourable overall survival rates in high-risk patients receiving induction therapy containing a proteasome inhibitor or an immunomodulatory drug, or both.
